In another study [39], 79% of newly diagnosed AML patients with IDH mutations achieved CRc (CR plus CR with incomplete hematologic recovery) after azacitidine combined with venetoclax treatment, and the 2-year OS rate was about 52.4%. The gene discussed is IDH1; the disease is acute myeloid leukemia.